Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Literature DB >> 16239380

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

D E Furst¹, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J W J Bijlsma, M Dougados, P Emery, E C Keystone, L Klareskog, P J Mease.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2005 PMID： 16239380 PMCID： PMC1766920 DOI： 10.1136/ard.2005.044941

Source DB: PubMed Journal: Ann Rheum Dis ISSN： 0003-4967 Impact factor: 19.103

× No keyword cloud information.

168 in total

Review 1. Assessment of patients with psoriatic arthritis: a review of currently available measures.

Authors: Dafna D Gladman; Philip Helliwell; Philip J Mease; Peter Nash; Christopher Ritchlin; William Taylor
Journal: Arthritis Rheum Date: 2004-01

Review 2. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

Authors: J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde
Journal: Ann Rheum Dis Date: 2003-09 Impact factor: 19.103

3. Treatment with infliximab for a child with Behçet's disease.

Authors: Frank T Saulsbury; James A Mann
Journal: Arthritis Rheum Date: 2003-08-15

4. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

Authors: Melike Melikoglu; Izzet Fresko; Cem Mat; Yilmaz Ozyazgan; Feride Gogus; Sebahattin Yurdakul; Vedat Hamuryudan; Hasan Yazici
Journal: J Rheumatol Date: 2005-01 Impact factor: 4.666

5. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.

Authors: Anthony Booth; Lorraine Harper; Tariq Hammad; Paul Bacon; Megan Griffith; Jeremy Levy; Caroline Savage; Charles Pusey; David Jayne
Journal: J Am Soc Nephrol Date: 2004-03 Impact factor: 10.121

6. Etanercept ameliorates sarcoidosis arthritis and skin disease.

Authors: Dinesh Khanna; Michael R Liebling; James S Louie
Journal: J Rheumatol Date: 2003-08 Impact factor: 4.666

7. Efficacy of infliximab in resistant psoriatic arthritis.

Authors: Carlo Salvarani; Fabrizio Cantini; Ignazio Olivieri; Pierluigi Macchioni; Angela Padula; Laura Niccoli; Maria Grazia Catanoso; Giovanni Lo Scocco; Luigi Boiardi
Journal: Arthritis Rheum Date: 2003-08-15

8. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens.

Authors: Shane A Curran; Oliver M FitzGerald; Patrick J Costello; Jeanette M Selby; David J Kane; Barry Bresnihan; Robert Winchester
Journal: J Immunol Date: 2004-02-01 Impact factor: 5.422

Review 9. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.

Authors: William D Tutrone; Rita Saini; Jeffery M Weinberg
Journal: IDrugs Date: 2004-01

10. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.

Authors: Philip N Hawkins; Helen J Lachmann; Ebun Aganna; Michael F McDermott
Journal: Arthritis Rheum Date: 2004-02

42 in total

Review 1. Biologic therapy for refractory scleritis: a new treatment perspective.

Authors: Tania Sales de Alencar de Fidelix; Luis Antonio Vieira; Denise de Freitas; Virginia Fernandes Moça Trevisani
Journal: Int Ophthalmol Date: 2015-08-29 Impact factor: 2.031

Review 2. Treatment of rheumatoid arthritis.

Authors: Paul Emery
Journal: BMJ Date: 2006-01-21

Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.

Review 1. Assessment of patients with psoriatic arthritis: a review of currently available measures.

Review 2. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.

3. Treatment with infliximab for a child with Behçet's disease.

4. Short-term trial of etanercept in Behçet's disease: a double blind, placebo controlled study.

5. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis.

6. Etanercept ameliorates sarcoidosis arthritis and skin disease.

7. Efficacy of infliximab in resistant psoriatic arthritis.

8. Nucleotide sequencing of psoriatic arthritis tissue before and during methotrexate administration reveals a complex inflammatory T cell infiltrate with very few clones exhibiting features that suggest they drive the inflammatory process by recognizing autoantigens.

Review 9. Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefacept.

10. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra.

Review 1. Biologic therapy for refractory scleritis: a new treatment perspective.

Review 2. Treatment of rheumatoid arthritis.

3. Consensus statement on the use of rituximab in patients with rheumatoid arthritis.

4. Neutropenia while receiving anti-tumour necrosis factor treatment for rheumatoid arthritis.

Review 5. Many cytokines are very useful therapeutic targets in disease.

6. Re-challenge with etanercept in patients with etanercept-induced neutropenia.

7. Tumour necrosis factor inhibitors and infection: What is there to know for infectious diseases physicians?

8. TNF-alpha and shear stress-induced large artery adaptations.

Review 9. Evidence that cytokines play a role in rheumatoid arthritis.

10. The CDK domain of p21 is a suppressor of IL-1beta-mediated inflammation in activated macrophages.